AU730307B2 - Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury - Google Patents

Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury Download PDF

Info

Publication number
AU730307B2
AU730307B2 AU10215/97A AU1021597A AU730307B2 AU 730307 B2 AU730307 B2 AU 730307B2 AU 10215/97 A AU10215/97 A AU 10215/97A AU 1021597 A AU1021597 A AU 1021597A AU 730307 B2 AU730307 B2 AU 730307B2
Authority
AU
Australia
Prior art keywords
bpi
bpi protein
protein product
corneal
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU10215/97A
Other languages
English (en)
Other versions
AU1021597A (en
Inventor
Patrick J. Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Royalty Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of AU1021597A publication Critical patent/AU1021597A/en
Application granted granted Critical
Publication of AU730307B2 publication Critical patent/AU730307B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU10215/97A 1995-11-14 1996-11-12 Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury Ceased AU730307B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55728995A 1995-11-14 1995-11-14
US08/557289 1995-11-14
PCT/US1996/018632 WO1997017990A1 (en) 1995-11-14 1996-11-12 Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury

Publications (2)

Publication Number Publication Date
AU1021597A AU1021597A (en) 1997-06-05
AU730307B2 true AU730307B2 (en) 2001-03-01

Family

ID=24224809

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10215/97A Ceased AU730307B2 (en) 1995-11-14 1996-11-12 Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury

Country Status (6)

Country Link
US (2) US20020128191A1 (enExample)
EP (1) EP0861088A1 (enExample)
JP (1) JP2000501386A (enExample)
AU (1) AU730307B2 (enExample)
CA (1) CA2235626C (enExample)
WO (1) WO1997017990A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1997004008A1 (en) * 1995-07-20 1997-02-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US7029712B1 (en) 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004006801A2 (en) * 2002-07-17 2004-01-22 Biosyntrx, Inc. Treatment for dry eye syndrome
GB0404374D0 (en) * 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
US20070185202A1 (en) * 2004-03-03 2007-08-09 University Of Georgia Research Foundation, Inc. Methods and compositions for ophthalmic treatment of fungal and bacterial infections
WO2007003481A1 (en) * 2005-07-01 2007-01-11 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016066A1 (en) * 1990-04-23 1991-10-31 Magainin Sciences Inc. Composition and treatment with biologically active peptides and toxic cations
AU4770596A (en) * 1995-01-13 1996-07-31 Xoma Corporation Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016066A1 (en) * 1990-04-23 1991-10-31 Magainin Sciences Inc. Composition and treatment with biologically active peptides and toxic cations
AU4770596A (en) * 1995-01-13 1996-07-31 Xoma Corporation Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products

Also Published As

Publication number Publication date
EP0861088A1 (en) 1998-09-02
WO1997017990A1 (en) 1997-05-22
CA2235626C (en) 2002-01-01
AU1021597A (en) 1997-06-05
US20030017986A1 (en) 2003-01-23
US20020128191A1 (en) 2002-09-12
JP2000501386A (ja) 2000-02-08
CA2235626A1 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
AU730303B2 (en) Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal transplantation
US5912228A (en) Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
Pflugfelder et al. Exogenous fungal endophthalmitis
AU741480B2 (en) Anti-chlamydial methods and materials
EP0754050A1 (en) Anti-gram-positive bacterial methods and materials
CA2235626C (en) Bactericidal permeability increasing protein (bpi) for treating conditions associated with corneal injury
AU3004397A (en) Therapeutic uses of bpi protein products for human meningococcemia
WO1996030037A1 (en) Method of treating conditions associated with burn injuries
US6670327B1 (en) Therapeutic uses of BPI protein products in humans with otitis media with effusion
AU5159698A (en) Therapeutic uses of bpi protein products in cystic fibrosis patients
US6509317B1 (en) Method of treating chronic cardiac disease
US6482796B2 (en) Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
CA2367943A1 (en) Therapeutic uses of bpi protein products in bpi-deficient humans
US20030194377A1 (en) Therapeutic uses of BPI protein products in cystic fibrosis patients
US20030027762A1 (en) Therapeutic uses of BPI protein products in BPI-deficient humans
AU2005202199B2 (en) Therapeutic uses of BPI protein products in humans with otitis media with effusion
MXPA99001366A (en) Anti-chlamydial methods and materials

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)